HSCS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

-0.880

-65.76%

-0.845

-55.05%

-0.820

-48.1%

Estimates Revision

The market is revising Upward the revenue expectations for HeartSciences Inc. (HSCS) for FY2026, with the revenue forecasts being adjusted by 1112.79% over the past three months. During the same period, the stock price has changed by -8.97%.

Revenue Estimates for FY2026

Revise Upward

+1112.79%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-1.55%

In Past 3 Month

Stock Price

Go Down

-8.97%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.50 USD with a low forecast of 9.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

10.50

High

12.00

Current: 0.000

Low

9.00

Averages

10.50

High

12.00

Ascendiant Capital

Lucas Ward

Strong Buy

Maintains

$15 → $14

2025-03-18

Reason

Ascendiant Capital

Lucas Ward

Price Target

$15 → $14

2025-03-18

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for HeartSciences Inc (HSCS.O) is -0.92, compared to its 5-year average forward P/E of -1.19. For a more detailed relative valuation and DCF analysis to assess HeartSciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.19

Current PE

-0.92

Overvalued PE

-0.26

Undervalued PE

-2.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.90

Current EV/EBITDA

-0.86

Overvalued EV/EBITDA

-0.00

Undervalued EV/EBITDA

-1.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

220.42

Current PS

33.27

Overvalued PS

1208.78

Undervalued PS

-767.93

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HSCS News & Events

Events Timeline

No data

News

3.5

2025-12-15Globenewswire

HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology

3.5

2025-12-15Newsfilter

HeartSciences Submits MyoVista Device for FDA 510(k) Clearance

4.0

2025-10-01Benzinga

Ascendiant Capital Reaffirms Buy Rating on HeartSciences, Reduces Price Target to $9

People Also Watch

Frequently Asked Questions

What is HeartSciences Inc (HSCS) stock price today?

The current price of HSCS is 3.35 USD — it has increased 9.48 % in the last trading day.

What is HeartSciences Inc (HSCS)'s business?

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

What is the price predicton of HSCS Stock?

What is HeartSciences Inc (HSCS)'s revenue for the last quarter?

HeartSciences Inc revenue for the last quarter amounts to 2.42K USD, decreased % YoY.

What is HeartSciences Inc (HSCS)'s earnings per share (EPS) for the last quarter?

HeartSciences Inc. EPS for the last quarter amounts to -0.85 USD, decreased -62.56 % YoY.

What changes have occurred in the market's expectations for HeartSciences Inc (HSCS)'s fundamentals?

How many employees does HeartSciences Inc (HSCS). have?

HeartSciences Inc (HSCS) has 15 emplpoyees as of January 09 2026.

What is HeartSciences Inc (HSCS) market cap?

Today HSCS has the market capitalization of 9.85M USD.